Related references
Note: Only part of the references are listed.Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials
T. Shiroiwa et al.
BRITISH JOURNAL OF CANCER (2009)
Costs Associated With Complications Are Lower With Capecitabine Than With 5-Fluorouracil in Patients With Colorectal Cancer
Edward Chu et al.
CANCER (2009)
Cost Implications of New Treatments for Advanced Colorectal Cancer
Yu-Ning Wong et al.
CANCER (2009)
XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis
Nikos Maniadakis et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
5LBA First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study)
D. Haller et al.
EJC SUPPLEMENTS (2009)
Effect of Rising Chemotherapy Costs on the Cost Savings of Colorectal Cancer Screening
Iris Lansdorp-Vogelaar et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Costs Associated with Capecitabine or 5-Fluorouracil Monotherapy after Surgical Resection in Patients with Colorectal Cancer
Edward Chu et al.
ONCOLOGY (2009)
Economic Impact of Alternative Adjuvant Chemotherapy Regimens for Stage III Colon Cancer
Martin Goerner et al.
ONKOLOGIE (2009)
The Economic Value of Innovative Treatments over the Product Life Cycle: The Case of Targeted Trastuzumab Therapy for Breast Cancer
Louis P. Garrison et al.
VALUE IN HEALTH (2009)
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
M. L. Rothenberg et al.
ANNALS OF ONCOLOGY (2008)
Capecitabine versus bolus fluorouracil plus leucovorin (Folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer - Economic evaluation in an Italian NHS setting
Francesco Di Costanzo et al.
CLINICAL DRUG INVESTIGATION (2008)
The CAP-CR study: Direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine
S. Lopatriello et al.
EUROPEAN JOURNAL OF CANCER (2008)
Projections of the costs associated with colorectal cancer care in the United States, 2000-2020
K. Robin Yabroff et al.
HEALTH ECONOMICS (2008)
Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer
Edward Chu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer
Jim Cassidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
Jim Cassidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adjuvant chemotherapy for colon cancer -: Analysis of treatment costs from the perspective of statutory sickness funds
M. Goerner et al.
ZEITSCHRIFT FUR GASTROENTEROLOGIE (2008)
Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan
Takeru Shiroiwa et al.
CLINICAL THERAPEUTICS (2007)
Using real-world data for coverage and payment decisions: The ISPOR real-world data task force report
Louis P. Garrison et al.
VALUE IN HEALTH (2007)
A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer
Marieke Krol et al.
EXPERT OPINION ON PHARMACOTHERAPY (2007)
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patients
Hans-Joachim Schmoll et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cancer statistics, 2007
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
Cost considerations in the treatment of colorectal cancer
Frank G. A. Jansman et al.
PHARMACOECONOMICS (2007)
Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting
J. Y. Douillard et al.
ONCOLOGY (2007)
Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
S. Eggington et al.
BRITISH JOURNAL OF CANCER (2006)
Xeloda® in adjuvant colon cancer therapy (X-ACT) trial:: Overview of efficacy, safety, and cost-effectiveness
Chris J. Twelves
CLINICAL COLORECTAL CANCER (2006)
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer
S. E. Ward et al.
BRITISH JOURNAL OF CANCER (2006)
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer:: the X-ACT trial
J Cassidy et al.
BRITISH JOURNAL OF CANCER (2006)
Costs and survival of patients with colorectal cancer in a health maintenance organization and a preferred provider organization
M Kerrigan et al.
MEDICAL CARE (2005)
Capecitabine as adjuvant treatment for stage III colon cancer
C Twelves et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds
A Grothey et al.
ZEITSCHRIFT FUR GASTROENTEROLOGIE (2005)
Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands
FGA Jansman et al.
CLINICAL THERAPEUTICS (2004)
American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer
AB Benson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Management of colorectal cancer in elderly patients - Focus on the cost of chemotherapy
MJ Matasar et al.
DRUGS & AGING (2004)
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial
W Scheithauer et al.
ANNALS OF ONCOLOGY (2003)
First-line oral capecitabine therapy in metastatic colorectal cancer:: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
J Cassidy et al.
ANNALS OF ONCOLOGY (2002)
Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials
C Twelves
EUROPEAN JOURNAL OF CANCER (2002)
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
PM Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
